8-​Prenylnaringenin

8-Prenylnaringenin is an orally active prenyl flavonoid. 8-Prenylnaringenin can be isolated from the hop spike Humulus lupulus. 8-Prenylnaringenin activates the PI3K/Akt pathway and the AMPK pathway, upregulates OXPHOS complexes (II, III, and V) and Sirt1, and reduces ROS production and SOD activity. 8-Prenylnaringenin improves muscle atrophy and obesity and inhibits angiogenesis. 8-Prenylnaringenin exhibits anticancer activity against glioblastoma and colon cancer. 8-Prenylnaringenin also has LH/FSH regulatory activity. 8-prenylnaringenin may be used in bone health research^{[1][2][3][4][5][6][7][8]}. In Vitro:8-Prenylnaringenin (48 h) exhibits strong inhibitory effect against human colon cancer HCT-116 cells with an IC₅₀ value of 23.83 μg/mL^[1].
8-Prenylnaringenin (0.1-10 μM; 0.25-4 h) activates the PI3K/Akt pathway in mouse C2C12 myotubes^[2].
8-Prenylnaringenin (10–500 μM; 24 h) shows higher cytotoxicity against human glioblastoma U-118 MG cells (IC₅₀ ≈ 138 μM) than normal BJ fibroblasts (IC₅₀ = 172 μM)^[3].
8-Prenylnaringenin (0.001-20 μM; 48 h) reduces reactive oxygen species (ROS) production, SOD activity in MCF-7 breast cancer cells^[4].
8-Prenylnaringenin inhibits BME cell invasion with IC₅₀ values ranging from 3 to 10 μM^[5].
8-Prenylnaringenin (1-30 μM) inhibits angiogenesis induced by bFGF, VEGF, or a combination of both cytokines in BME cells in a dose-dependent manner^[5].
In Vivo:8-Prenylnaringenin (0.05% wt/wt in diet for male mice, 0.00005-0.0005% wt/wt in diet for female mice; p.o. via mixed diet) promotes recovery from immobilization-induced disuse muscle atrophy in C57/BL6 mice by activating the Akt phosphorylation pathway^[2].
8-Prenylnaringenin (0.0005%-0.005% wt/wt in high-fat diet; p.o. via mixed diet; 8 weeks) prevents high-fat diet-induced obesity in C57BL/6J male mice by promoting adiponectin secretion and activating the AMPK pathway^[6].
8-Prenylnaringenin (126-1260 ppm; p.o. via soy-free diet; 3 months) suppresses serum LH/FSH levels and stimulates uterine weight in ovariectomized Sprague-Dawley rats^[7].
8-Prenylnaringenin (1.77 mg/kg; s.c.; daily; 10 weeks) does not improve biomechanical properties or bone mineral density of lumbar vertebrae and femora in ovariectomized Sprague-Dawley rats^[8].